This indicated a promising solution for anti‐tumor therapy by targeting abnormal tumor ECM.[126] Another study uncovered that the T cell cytotoxicity against malignant mammary gland carcinoma cells varied upon different ECM compositions, where the function of T cells was defective in malignant mammary gland carcinoma cells/T cell cocultures on collagen IV while it was effective on vitronectin.[127] All these examples suggest that the mechanics of ECM may be a novel therapeutic target for immune‐related disorders. This evidence concerns the gene VTN and neoplasm.